LCM
RXRX icon

Laurion Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Laurion Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,547,407
Closed -$8.19M – 486
2025
Q1 		$8.19M Sell
1,547,407
-909,782
-37% -$6.63M 0.21% 83
2024
Q4 		$16.6M Buy
+2,457,189
New +$16.5M 0.3% 69
2024
Q3 		– Sell
-2,901,134
Closed -$21.8M – 555
2024
Q2 		$21.8M Buy
2,901,134
+1,993,518
+220% +$17.4M 0.26% 66
2024
Q1 		$9.05M Hold
907,616
– – 0.08% 205
2023
Q4 		$8.95M Hold
907,616
– – 0.08% 194
2023
Q3 		$6.94M Sell
907,616
-2,270,563
-71% -$22.7M 0.04% 249
2023
Q2 		$23.7M Sell
3,178,179
-1,647,556
-34% -$11.5M 0.13% 136
2023
Q1 		$32.2M Hold
4,825,735
– – 0.22% 106
2022
Q4 		$37.2M Buy
4,825,735
+238,461
+5% +$2.34M 0.17% 128
2022
Q3 		$48.8M Hold
4,587,274
– – 0.29% 87
2022
Q2 		$37.3M Hold
4,587,274
– – 0.58% 43
2022
Q1 		$32.8M Buy
4,587,274
+663,561
+17% +$7.05M 0.4% 55
2021
Q4 		$67.2M Hold
3,923,713
– – 0.68% 29
2021
Q3 		$90.3M Buy
3,923,713
+65,096
+2% +$1.84M 0.38% 68
2021
Q2 		$141M Buy
+3,858,617
New +$114M 0.78% 26

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Laurion Capital Management's RXRX Position: Q2 2025 in Review

Laurion Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 1,547,407 shares — an estimated $8.19M sold.

Laurion Capital Management first reported a position in RXRX in Q2 2021 and held it in 15 quarters. The position peaked at $141M in Q2 2021. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Laurion Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Laurion Capital Management sold 1,547,407 Recursion Pharmaceuticals shares in Q2 2025, an estimated $8.19M.
  • Laurion Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 15 quarters.
  • Laurion Capital Management's Recursion Pharmaceuticals position peaked at $141M in Q2 2021.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Laurion Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.